$-15.49
(Market cap
$61 Mln
Recently Viewed
Clear AllMarket cap
$61 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.2
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
3,342,880
CFO
$-180.07 Mln
EBITDA
$-211.03 Mln
Net Profit
$-199.12 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Reneo Pharmaceuticals (RPHM)
| -88.7 | -87.3 | -88.0 | -97.4 | -70.7 | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Reneo Pharmaceuticals (RPHM)
| -31.3 | -72.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Reneo Pharmaceuticals (RPHM)
|
1.8 | 60.8 | 1.5 | -56.5 | -4,286.6 | -68.3 | -- | 0.8 |
| 0.0 | 0.7 | 1.0 | -84.3 | -917.2 | -- | -- | 0.0 |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and... selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. Read more
Founder & Executive Chairman
Mr. Michael G. Grey
Founder & Executive Chairman
Mr. Michael G. Grey
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Reneo Pharmaceuticals Inc (RPHM) is $1.81 (NASDAQ) as of 04-Oct-2024 18:32 EDT. Reneo Pharmaceuticals Inc (RPHM) has given a return of -70.72% in the last 3 years.
Since, TTM earnings of Reneo Pharmaceuticals Inc (RPHM) is negative, P/E ratio is not available.
The P/B ratio of Reneo Pharmaceuticals Inc (RPHM) is 0.79 times as on 04-Oct-2024, a 83 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Reneo Pharmaceuticals Inc (RPHM) are Rs -- and Rs -- as of 25-Apr-2026.
Reneo Pharmaceuticals Inc (RPHM) has a market capitalisation of $ 61 Mln as on 04-Oct-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Reneo Pharmaceuticals Inc (RPHM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.